NicOx : Garufi ... e la Rivoluzione Pharma
- Creatore Discussione Yesod
- Data di Inizio
- Stato
guly
Forumer storico
questa me la segno.....................
nel frattempo voglio divertirmi con un altro ottimo titolino del nasdaq che ho cominciato a seguire,sta partendo oggi ha fatto un +10 e dovrebbe essere un aperitivo.domani vedo smobilizzo un altro po' di nicox e entro con un cip.chissa' che vada bene.un blitz da una 15 di giorni e poi si rientra.quante occasioni perdute aspettando nicox.
doctor NO
NO nel DNA
Beh certo che a leggervi in sintonia con il piccolo chimico di finanza on line siete un bel gruppetto di sfigheiras
doctor NO
NO nel DNA
ho cominciato ad operare inizi anni 80 e credimi che di pirla ne ho visti a sciami
anch'io ho preso le mie cantonate ma l'esperienza insegna
vedrai che presto imparerai a tue spese
mangime eri mangime ritorni
buon appetito kaimano
doctor NO
NO nel DNA
"NEWS" DU 26/05/09 18H Auj. à 21:00
NicOx to shift from nitric oxide-donating approach
Today
Christopher Spillane
NicOx has told Scrip that its future business does not completely lie in nitric oxide-donating compounds, a mainstay of its business since its inception in 1996. The French firm said that it will start to step away from its traditional focus as it seeks to become a commercial operation.
"It's most likely the next things we bring in to feed the pipeline are not going to come from nitric-oxide donating compounds at all," said Dr Gavin Spencer, vice-president of business development.
Although its commercial outlook would move from NO-donating compounds, NicOx reiterated the strength of its R&D scope, adding that "there's still a lot to be done with the technology".
Just last month, the firm acquired Nitromed's NO-donating compounds in a €6 million deal that handed it the strongest intellectual property for the technology worldwide (scripnews.com, April 24th, 2009).
The company's lead product naproxcinod, for patients with osteoarthritis of the knee and hip, symbolises its development history of nitric-oxide donating compounds.
The Phase III compound met its co-primary efficacy endpoints in its third pivotal trial. However, NicOx says that its mechanism lowers blood pressure unlike other anti-inflammatories, like NSAIDS, which have been linked with increased risk of heart attack and stroke (scripnews.com, December 2nd, 2008).
NicOx plans to commercialise the product in the US first before moving it into the European market, while its other regional rights will be licensed out. The firm will market naproxcinod using a 150-plus sales force in a specialty area and will partner it with a company which has a strong primary care presence.
Discussing NicOx's drive towards becoming a commercial operation, Sanjiv Sharma, commercial vice-president, said: "Our wish list would be to have someone with a product already in the market – not necessarily a big product – it could be as simple as doing a little co-promotion deal with another company because we have spare capacity."
"In the mid-to-long term we would develop our own pipeline products and in-license pipeline products and develop them into the market," he added.
ACCEE UNIQUEMENT ABONNES
NicOx to shift from nitric oxide-donating approach
Today
Christopher Spillane
NicOx has told Scrip that its future business does not completely lie in nitric oxide-donating compounds, a mainstay of its business since its inception in 1996. The French firm said that it will start to step away from its traditional focus as it seeks to become a commercial operation.
"It's most likely the next things we bring in to feed the pipeline are not going to come from nitric-oxide donating compounds at all," said Dr Gavin Spencer, vice-president of business development.
Although its commercial outlook would move from NO-donating compounds, NicOx reiterated the strength of its R&D scope, adding that "there's still a lot to be done with the technology".
Just last month, the firm acquired Nitromed's NO-donating compounds in a €6 million deal that handed it the strongest intellectual property for the technology worldwide (scripnews.com, April 24th, 2009).
The company's lead product naproxcinod, for patients with osteoarthritis of the knee and hip, symbolises its development history of nitric-oxide donating compounds.
The Phase III compound met its co-primary efficacy endpoints in its third pivotal trial. However, NicOx says that its mechanism lowers blood pressure unlike other anti-inflammatories, like NSAIDS, which have been linked with increased risk of heart attack and stroke (scripnews.com, December 2nd, 2008).
NicOx plans to commercialise the product in the US first before moving it into the European market, while its other regional rights will be licensed out. The firm will market naproxcinod using a 150-plus sales force in a specialty area and will partner it with a company which has a strong primary care presence.
Discussing NicOx's drive towards becoming a commercial operation, Sanjiv Sharma, commercial vice-president, said: "Our wish list would be to have someone with a product already in the market – not necessarily a big product – it could be as simple as doing a little co-promotion deal with another company because we have spare capacity."
"In the mid-to-long term we would develop our own pipeline products and in-license pipeline products and develop them into the market," he added.
ACCEE UNIQUEMENT ABONNES
guly
Forumer storico
Beh certo che a leggervi in sintonia con il piccolo chimico di finanza on line siete un bel gruppetto di sfigheiras
vedo che ti impicci pero'.visto che non siamo attendibili a qual pro?
doctor NO
NO nel DNA
sbircio
leggere caxxate lo trovo un passatempo un relax manca il corvo nel teatrino e poi lo spettacolo può iniziare- Stato